Mantle Cell Lymphoma

The combination of ibrutinib and palbociclib appeared to be a feasible and active treatment regimen in patients with previously treated mantle cell lymphoma, according to findings from a phase I dose-finding study recently published in <em>Blood</em>.

Krish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.

The&nbsp;investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA&nbsp;for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy,&nbsp;BeiGene, the company manufacturing the agent, has announced.

Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.

Krish Patel, MD,&nbsp;discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Autologous hematopoietic cell transplantation consolidation after induction therapy may improve progression-free survival in younger, fit patients with mantle cell lymphoma, according to the results of a retrospective analysis recently published in the <em>Journal of Clinical Oncology. </em>

Jonathon B. Cohen, MD, MS, discussed his treatment considerations and decisions for treating patients with mantle cell lymphoma. Cohen made these decisions based on a case scenario of a patient with advanced-stage MCL.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

Measuring circulating tumor DNA in the blood of patients with advanced MCL may be a viable way to predict how well they will respond to specific therapies, according to study findings reported at the 2018 ASH Annual Meeting.

In findings reported during the 2018 ASH Annual Meeting,&nbsp;brentuximab vedotin with conventional chemotherapy significantly improved&nbsp;progression-free survival compared with standard therapy for nonpediatric patients&nbsp;with stage III/IV Hodgkin lymphoma.

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab&nbsp; in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.

The shift in the pattern of care in mantle cell lymphoma to bendamustine and rituximab in the frontline has resulted in an improvement in event-free survival compared with the era in which R-CHOP dominated front-line treatment.

Long-term follow-up of patients with relapsed or refractory mantle cell lymphoma treated with venetoclax monotherapy indicate that remissions are durable in a meaningful proportion and that late-onset toxicities are uncommon.

Combination therapy with acalabrutinib plus bendamustine and rituxumab showed an overall response rate in excess of 90% of patients with treatment-na&iuml;ve mantle cell lymphoma and an ORR of 85% in patients with relapsed/refractory disease in an ongoing open-label phase Ib study.^&nbsp;The safety profile was consistent with expected safety profiles for acalabrutinib and BR, said Tycel Phillips, MD, who presented the data at the 2018 American Society of Hematology Annual Meeting.

According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in&nbsp;<em>Lancet Oncology</em>.

Durable responses were achieved with acalabrutinib therapy for patients with relapsed/refractory mantle cell lymphoma, with 40% still on treatment for more than 2 years, according to long-term follow-up findings presented at the 2018 ASH Annual Meeting.

Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of&nbsp;a phase II trial.<br /> &nbsp;

In an interview with&nbsp;<em>Targeted Oncology</em>, Jonathon B. Cohen, MD, discussed the evolving treatment landscape of MCL.

The FDA has granted approval to the&nbsp;rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy, making it the first&nbsp;biosimilar approved by the FDA for the treatment of patients with NHL.

Using the VR-CAP regimen instead of R-CHOP significantly improved median overall survival in previously untreated newly diagnosed patients with mantle cell lymphoma who were not eligible for transplant, according to results from the long-term follow-up phase of a randomized, open-label, phase III trial.

According to Robert Dean, MD, BTK inhibitors and CAR T cells may fulfill an unmet need in patients with mantle cell lymphoma. Experts have been hard-pressed to find long-lasting treatments like these that have the potential to impact this patient population.

Jonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.

During a presentation at the National Comprehensive Cancer Network 13th Annual Conference: Hematologic Malignancies Phillippe Armand, MD, PhD, discusses how novel agents could be used in the future either to postpone, permit, or even replace allogeneic stem cell transplantation.